A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma

This is a Phase Ib, open-label study to determine the safety and preliminary efficacy of PRJ1-3024 in China subjects with unresectable local advanced or metastatic melanoma

Trial Details

NCT ID
NCT06727630
Phase
PHASE1 / PHASE2
Sponsor
Zhuhai Yufan Biotechnologies Co., Ltd
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • PRJ1-3024
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Male or non-pregnant, non-lactating female subjects aged ≥18 years.
  • ECOG Performance Status 0\~1.
  • Has at least 1 measurable lesion as defined by RECIST 1.1 criteria.
  • Life expectancy of ≥3 months, in the opinion of the Investigator.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →